MYCAMINE 100 MG
MICAFUNGIN SODIUM : 100 MG · DIN 02311054 · SANDOZ CANADA INCORPORATED
Health Canada status: CANCELLED POST MARKET
What is MYCAMINE?
MYCAMINE 100 MG contains MICAFUNGIN SODIUM : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02311054, held by SANDOZ CANADA INCORPORATED, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 31-Jul-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MYCAMINE used for?
Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses; Esophageal candidiasis; Prophylaxis of Candida infections in HSCT recipients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02311054 |
|---|---|
| Brand name | MYCAMINE |
| Generic / active ingredient | MICAFUNGIN SODIUM : 100 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 100 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J02AX05 MICAFUNGIN |
| AHFS class | 08:14.16 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 31-Jul-2026 |
| Original market date | 2009-12-17 00:00:00 |
How is it administered?
Administer by slow IV infusion over 1 hour. Adults: 50-150 mg/day depending on indication. Pediatrics (≥4 months): 1-2 mg/kg/day (max 100-150 mg/day). Do not mix with other medications.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. (Note: Summary Product Information table lists storage in general terms; specific room temperature range is standard).
How is it supplied?
50 mg and 100 mg single-use vials.
Contraindications
Hypersensitivity to micafungin, other echinocandins, or any component of the formulation.
Warnings and precautions
Serious hypersensitivity (anaphylaxis), Stevens-Johnson syndrome, and TEN reported. Potential risk of liver tumors (based on rat studies). Monitor hepatic, renal, and hematological (hemolysis) function.
Is MICAFUNGIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by OMEGA LABORATORIES LIMITED, last seen 10 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J02AX05 MICAFUNGIN. 6 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MICAFUNGIN SODIUM FOR INJECTION | 100 MG | POWDER FOR SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02547236 |
| MICAFUNGIN SODIUM FOR INJECTION | 100 MG | POWDER FOR SOLUTION | JUNO PHARMACEUTICALS CORP. | MARKETED | DIN 02524961 |
| MICAFUNGIN SODIUM FOR INJECTION | 100 MG | POWDER FOR SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02532360 |
| MICAFUNGIN SODIUM FOR INJECTION | 50 MG | POWDER FOR SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02532344 |
| MICAFUNGIN SODIUM FOR INJECTION | 50 MG | POWDER FOR SOLUTION | JUNO PHARMACEUTICALS CORP. | MARKETED | DIN 02524953 |
| MICAFUNGIN SODIUM FOR INJECTION | 50 MG | POWDER FOR SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02547228 |
| MICAFUNGIN FOR INJECTION | 100 MG | POWDER FOR SOLUTION | ACCORD HEALTHCARE INC | APPROVED | DIN 02543176 |
| MICAFUNGIN FOR INJECTION | 50 MG | POWDER FOR SOLUTION | ACCORD HEALTHCARE INC | APPROVED | DIN 02543168 |
| MYCAMINE | 50 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02294222 |
Who else supplies MICAFUNGIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MICAFUNGIN appears in 42 registered pack listings across 8 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.